Revenio Group Oyj · OMXHEX:REG1V
Revenio Group Oyj — Merger or Acquisition (April 2026)
37 slides from Revenio Group Oyj's merger presentation, Apr 13, 2026
Slide 1: Revenio accelerates growth and value creation by joining forces with Visionix
Revenio accelerates growth and value creation by joining forces with Visionix April 13, 2026 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by, and the information contained herein (unless otherwise indicated) has been provided by, Revenio Group Corporation (“Revenio”) and in relation to Revenio buying all the shares in LT International SAS (“Visionix”) (the “Acquisition”). By attending the
Slide 3: We aspire to keep the wonderful world visible for all
We aspire to keep the wonderful world visible for all. 3
Slide 4: Presenting today
Presenting today Jouni Toijala Robin Pulkkinen Chief Executive Officer Chief Financial Officer 4
Slide 5: Today's agenda
Today’s agenda Joining forces Transaction Discussion with Visionix details and Q&A Jouni Toijala Robin Pulkkinen 5
Slide 6: Revenio accelerates growth and value creation by joining forces with Visionix
Revenio accelerates growth and value creation by joining forces with Visionix Revenio joins forces with Visionix and becomes a leading turnkey solutions provider in the global eye care market. The rationale of the transaction is to bring together two highly complementary businesses, enabling acceler
Slide 7: Introduction to Visionix
Introduction to Visionix Company overview Key figures, 2025 • A French company founded in 1994 by Dr. Marc Abitbol Net sales Adjusted EBITDA Users • Specializes in innovative eye care devices supported by a cloud-based software platform € 143.4M € 16.6M 135,000 • Multinational company with operation
Slide 8: Creating a leading turnkey solutions provider in the global eye care market
Creating a leading turnkey solutions provider in the global eye care market 2.5x increase in addressable market Combined key financials (illustrative) Geographical coverage Other 1.5 Net sales Adj. EBITDA Sales in Fundus 0.5 253 48 138 Largest markets imaging MEUR MEUR countries $4.0 bn by sales vol
Slide 9: Path to accelerated growth and value creation
Path to accelerated growth and value creation Highly complementary product, 1. software and customer portfolios Approximately 2.5x increase in total addressable 2. market and expedited entry to the OCT segment Targeting more than EUR 20M EBITDA uplift through joint 3. value creation and synergies by
Slide 10: 1. Highly complementary product, software and customer portfolios
1 2 3 1. Highly complementary product, software and customer portfolios The transaction significantly expands Revenio’s product offering to include new diagnostic, refraction and finishing solutions • Highly complementary products and solutions with only limited overlap, creating a seamlessly connec
Slide 11: Comprehensive product and software portfolio
1 2 3 Comprehensive product and software portfolio… Tonometers Perimetry Fundus Multimodal OCT Refraction Edging & Software & imaging devices systems Mounting telehealth iCare ALTIUS iCare iCare iCare IC100 & iCare MAIA iCare EIDON family ILLUME HOME2 IC200 iCare RETCAD iCare iCare iCare iCare COMPA
Slide 12: Providing a turnkey solution for optical retail and optometry
1 2 3 ...providing a turnkey solution for optical retail and optometry... Optometric customer journey Pre-test / Screening Refractive / Clinical examination Finishing & dispensing Connecting platform & clinical data management 12
Slide 13: Across ophthalmic pathologies, positioned for the future of advanced eye care
1 2 3 ….across ophthalmic pathologies, positioned for the future of advanced eye care Glaucoma Retinal Cataracts Corneal Dry eye Refractive diseases issues syndrome errors iCare IC100 & iCare IC200, iCare HOME2, iCare probes iCare DRSplus, iCare EIDON iCare COMPASS iCare MAIA Optovue Solix (OCT) VX
Slide 14: Product portfolio expansion in several customer segments
1 2 3 Product portfolio expansion in several customer segments Optical retail Ophthalmology Optometry Substantial access to the optical retail segment is a key addition for Revenio Pharma research Home care Other healthcare & universities 14
Slide 15: 2. Approximately 2.5x increase in total addressable market and entry to OCT
1 2 3 2. Approximately 2.5x increase in total addressable market and expedited entry to the OCT segment As a result of the transaction, Revenio’s addressable market in ophthalmic diagnostic equipment increases by approximately 2.5x to around USD 2.5 billion • Strategically compelling entry into the
Slide 16: OCT is at the center of ophthalmic diagnostics
1 2 3 OCT is at the center of ophthalmic diagnostics OCT = Optical Coherence Tomography OCT Increasing prevalence of Growing interest among eye disease requiring clinicians for combining diagnostic accuracy and OCT and fundus imaging disease management OCT is becoming the Early detection capabilitie
Slide 17: 3. Targeting more than EUR 20M EBITDA uplift through synergies by end of 2029
1 2 3 3. Targeting more than EUR 20M EBITDA uplift through joint value creation and synergies by the end of 2029 Commercial levers to boost sales growth: More than • Optimizing route-to-market and channels EUR 20M • Cross-selling to existing customers • Capturing new customers with unified offering
Slide 18: Improved route-to-market with substantial opportunities in channel optimization
1 2 3 Improved route-to-market with substantial opportunities in channel optimization… The transaction significantly enhances Revenio’s route-to- market, including coverage in seven new countries through Visionix’ direct sales force • Larger combined sales volumes create opportunities to leverage co
Slide 19: Opportunities in cross-selling and new customer segments
1 2 3 ...and opportunities in cross-selling and new customer segments Leveraging existing customer relationships to cross-sell across selected categories with complementary product functionalities • Highest identified potential particularly in OCT and imaging • Additional sales and entry into previo
Slide 20: A game changing combination – leading position in several geographies
1 2 3 A game changing combination – leading position in several geographies Pre-deal sales split, FY25 (EUR million) Post-deal sales split, FY25 (EUR million) Combined, illustrative 26% 32% 34% 110 48% 2% 253 1% 3% 1% 3% 4% 6% 4% 16% 5% 10% 6% United States United Kingdom France Spain Germany Austra
Slide 21: Scale benefits, cost savings and other synergies
1 2 3 Scale benefits, cost savings and other synergies The transaction is expected to deliver scale benefits, resulting in selected cost synergies • The main savings in operating expenses will come from integrating and optimizing overlapping functions and IT systems • Cost-saving potential through c
Slide 22: A phased value creation journey
A phased value creation journey 2026-2027 2028-2029 Beyond 2030 Quick wins & Mobilization Traction & Build-Up Continued growth & Sustained leadership • Combine organizations, processes and • Harvest full cross-sell synergies through • Extend market leadership through our system landscapes unified pl
Slide 23: Transaction details
Transaction details 23
Slide 24: Transaction terms and financing in brief
Transaction terms and financing in brief Revenio will acquire the entire share capital of LT International SAS, the parent company of Visionix International group Key transaction terms Transaction financing EUR 40 million Term loan facility Refinancing of EUR 130 million Net debt, NWC and 3rd party
Slide 25: Resolutions to be proposed to the General Meeting
Resolutions to be proposed to the General Meeting The completion of the transaction is subject to Revenio’s General Meeting resolving to: • Authorize the Board of Directors of Revenio to decide on a directed share issue of 2,485,797 new shares to the sellers in connection with the completion of the
Slide 26: Transaction impact on Revenio's ownership
Transaction impact on Revenio’s ownership Revenio shareholders after completion of the transaction Comments Name Shares per % Shares after % • As part of the consideration, the 31.3.2026 completion 1) sellers have irrevocably committed to William Demant Invest 6,532,461 24.48% 6,532,461 22.40% subsc
Slide 27: Post-completion rights issue
Post-completion rights issue Revenio plans to execute a EUR 80 million post-completion rights issue, subject to the decision of the General Meeting • Nordea has been engaged to act as the global coordinator and underwriter for the rights issue • Targeted to be arranged during mid to late H2/2026 • W
Slide 28: Combined illustrative financials
Combined illustrative financials 2025 2025 2025 1 EUR thousand, unless otherwise IFRS IFRS IFRS indicated Leverage ratios will Revenio Visionix Combined, unaudited2) improve with post- Net sales 109,6771) 143,4081) 253,085 transaction rights issue, Adjusted EBITDA3) 31,038 16,559 47,597 which is use
Slide 29: Leveraging the best of both companies
Leveraging the best of both companies Governance and group structure Key principles guiding the going forward target operating model design Following completion of the transaction, Visionix will be integrated into Revenio’s group structure. Maximize synergies and The combined group will operate unde
Slide 30: Withdrawal of financial guidance for 2026
Withdrawal of financial guidance for 2026 Due to the transaction, Revenio withdraws its previous financial guidance and will provide updated financial guidance for 2026 after the completion of the transaction. Revenio’s previous financial guidance, published on February 11, 2026: Revenio Group’s exc
Slide 31: Estimated one-off costs related to integration and achievement of synergies
Estimated one-off costs related to integration and achievement of synergies Based on Revenio’s assessment, the integration process and achieving the targeted synergies will require one-off costs of approximately EUR 20 million of which approximately 30% will be capitalized (related to IT). These one
Slide 32: Transaction timeline
Transaction timeline April May June H2/2026 April 13 May (TBC) By the end of Q2 Integration and value creation Post-completion Signing of the Annual Completion of the implementation begins rights issue (targeted to be arranged transaction General transaction in mid to late H2) Meeting 32
Slide 33: Discussion
Discussion Marc Abitbol Arne Boye Nielsen Charles Vilgrain CEO, Chair of the Board, Managing Partner, Visionix Revenio Group Caravelle Capital 33
Slide 34: Summary
Sen. REVENIO
Slide 35: Accelerated growth and value creation with greater scale and synergies
Accelerated growth and value creation with greater scale and synergies Total Targeting addressable ~$1 bn ~$2.5 bn 3x market market growth Portfolio Limited Comprehensive Approaching Route-to-market and sales Sub-scaled Scaled 30% EBITDA channels beyond 2030 + Scale benefits and synergies 35
Slide 36: rans OCQT TT
rans OCQT TT REVENIO
Slide 37: Slide 37